The right antibody.
By design, not by chance.
Formula-Y designs antibodies in silico with AI, then partners with labs to validate them in vitro, so research and biotech teams reach reliable candidates faster.
To offer the fastest antibody discovery services in the world.
We empower researchers and biotech teams to accelerate antibody discovery through high-performance in-silico and in-vitro pipelines optimised for speed and reliability.
Antibody design, reimagined with AI.
We design candidates computationally, before a single experiment runs. Here is what that changes.
Vast design space
Models explore sequence and structure space far beyond nature's antibody repertoire.
Before the bench
Candidates are proposed and ranked before any wet-lab work begins.
Fewer dead ends
Higher hit rates, and far fewer experiments spent chasing candidates that never had a chance.
Hard targets
New routes toward difficult, historically hard-to-drug targets.
From the right target to a designable antibody.
Antibody discovery has two make-or-break decisions. Formula-Y brings AI to both, before the lab work starts.
Identify the right target
Every program starts with one high-stakes question: which molecule should the antibody bind? We use AI to analyse biological data and prioritise the most promising, disease-relevant targets before committing resources.
Target identificationDesign the antibody
Our AI models design antibody candidates against the chosen target computationally, and rank them before any experiment runs. The result is a shortlist worth taking to the bench, instead of a library to screen.
AI-driven designValidate with partners
Top-ranked candidates are handed off for in-vitro testing with lab partners. Results feed back to sharpen the models, closing the loop between computation and the bench.
In-vitro validationPartner with us on validation.
Formula-Y designs antibodies in silico. We are looking for collaborators and partners to take those AI-designed antibodies into in-vitro validation, and to build antibody programs together. If your lab can validate designed antibodies at the bench, we would love to talk.
Backed by regional and European innovation programmes.
Formula-Y's approach has been supported through successive subsidies from SNN, the Just Transition Fund and the European Union.
VIA Groningen 2025 to 2026: Proof of concept for AI-designed antibodies
Our current flagship project: building and testing the proof of concept for Formula-Y's AI-driven antibody design, on the way to a validated design service.
Read moreMIT Haalbaarheid 2025: AI for target identification
A feasibility study into whether AI can make target identification, the first and most consequential choice in any antibody program, faster, cheaper and more systematic.
Read moreMIT Haalbaarheid 2023: Proving the case for AI-designed antibodies
The feasibility study that started it all: a structured technical and economic assessment confirming that AI-driven antibody design is both viable and worth building.
Read moreThe people behind Formula-Y.
A small team combining platform engineering with deep immunology, genomics and bioinformatics.
Let's talk antibodies.
Partnerships, collaborations, or questions about the platform: send a note and we'll get back to you. Prefer email? Write to info@formula-y.com.